<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056974</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A232-HIV</org_study_id>
    <nct_id>NCT05056974</nct_id>
  </id_info>
  <brief_title>A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs</brief_title>
  <official_title>A Phase II Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide for the Shock-block-kill Mechanism in Changing HIV Reservoirs Among ART Stabilized HIV-1 Patients Who Undergo ART Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421&#xD;
      monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1&#xD;
      adults with stably viral suppression who undergo ART interruption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV cell-associated RNA levels</measure>
    <time_frame>Day 21, 56, 98</time_frame>
    <description>The change in HIV-1 Total DNA from baseline at the ninth week after the first administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 Total DNA levels</measure>
    <time_frame>Day 21, 56, 98</time_frame>
    <description>The changes in HIV-1 Total DNA levels during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>UB-421 + chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-421 + chidamide combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-421</intervention_name>
    <description>10 mg/kg, weekly, Subjects will receive weekly UB-421 during the 8-week</description>
    <arm_group_label>UB-421 + chidamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chidamide</intervention_name>
    <description>10 mg/dose, twice a week for 8 weeks, at the interval of no less than 3 days between the two doses.</description>
    <arm_group_label>UB-421 + chidamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 sero-positive, with documented HIV-1 infection by official, signed, written&#xD;
             history&#xD;
&#xD;
          2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg, aged 20 years or&#xD;
             older.&#xD;
&#xD;
          3. No breastfeeding or pregnancy for women.&#xD;
&#xD;
          4. Have been receiving ART for more than 3 years by screening visit 1 (SV1).&#xD;
&#xD;
          5. Both male and female patients and their partners of childbearing potential must agree&#xD;
             to use 2 medically accepted methods of contraception&#xD;
&#xD;
          6. Subjects must sign the informed consent before undergoing any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with active systemic infections, except for HIV-1&#xD;
&#xD;
          2. Any exposure to a monoclonal antibody within 12 weeks prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          3. Current receiving treatment regimen for hepatitis B, hepatitis C or latent&#xD;
             tuberculosis&#xD;
&#xD;
          4. Any alcohol or illicit drug use&#xD;
&#xD;
          5. Receipt of any other investigational study agent(s) within 90 days before SV2.&#xD;
&#xD;
          6. Currently on the treatment for diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mico Hsu</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3201</phone_ext>
    <email>mico.hsu@unitedbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghao Shi</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3204</phone_ext>
    <email>zhonghao.shi@unitedbiopharma.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>UB-421</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

